You are here

psoriasis

AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis

AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque Psoriasis

Motley Fool

Boehringer Ingelheim

Flag link:

Durect shares rocked by midstage psoriasis flop, shifts focus to liver disease

Durect shares rocked by midstage psoriasis flop, shifts focus to liver disease

Fierce Biotech

clinical trials

Flag link:

UCB posts more supportive data from Humira rival bimekizumab

UCB posts more supportive data from Humira rival bimekizumab

Pharmaforum

Flag link:

Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla

Amgen juices up sales outlook amid high hopes for Celgene castoff Otezla

Fierce Pharma

Flag link:

UCB adds on more positive PhIII data for IL-17A/17F inhibitor bimekizumab, clearing a path to the FDA

UCB adds on more positive PhIII data for IL-17A/17F inhibitor bimekizumab, clearing a path to the FDA

Endpoints

clinical trials

Flag link:

Johnson & Johnson's Tremfya backs psoriatic arthritis play with newest data

Johnson & Johnson's Tremfya backs psoriatic arthritis play with newest data

Fierce Pharma

psoriatic arthritis

clinical trials

Flag link:

J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis

J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis

BioSpace

clinical trials

Flag link:

UCB's bispecific beats J&J's Stelara in psoriasis phase 3

UCB's bispecific beats J&J's Stelara in psoriasis phase 3

Fierce Biotech

bispecific antibodies

Flag link:

UCB tries to win some respect in the crowded psoriasis market with a dual IL-17 approach — and it won't be easy

UCB tries to win some respect in the crowded psoriasis market with a dual IL-17 approach — and it won't be easy

Endpoints

Flag link:

Sienna Biopharmaceuticals Files for Bankruptcy, Delaying Phase III Psoriasis Trial

Sienna Biopharmaceuticals Files for Bankruptcy, Delaying Phase III Psoriasis Trial

BioSpace

Sienna Biopharmaceuticals

Flag link:

Skyrizi looks ready to soar after strong launch

Skyrizi looks ready to soar after strong launch

Biopharma Dive

Flag link:

Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger

Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger

Stat

Bristol-Myers Squibb

Flag link:

5 Biggest New Drugs Approved in 2019 So Far

5 Biggest New Drugs Approved in 2019 So Far

Motley Fool

multiple sclerosis

metastatic bladder cancer

Flag link:

Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt

Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt

Fierce Pharma

Flag link:

AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib

AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib

Fierce Pharma

rheumatoid arthritis

Flag link:

Eli Lilly's Taltz touts long-term clear skin data after unimpressive first-quarter sales

Eli Lilly's Taltz touts long-term clear skin data after unimpressive first-quarter sales

Fierce Pharma

Flag link:

Ramaswamy's Dermavant Updates $124 Million IPO Filing

Ramaswamy's Dermavant Updates $124 Million IPO Filing

CP Wire

Vivek Ramaswamy

Flag link:

Ramaswamy's Dermavant Updates $124 Million IPO Filing

Flag link:

AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst

AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst

Fierce Pharma

Flag link:

AbbVie successor to Humira in psoriasis gains FDA approval

AbbVie successor to Humira in psoriasis gains FDA approval

BioCentury

Flag link:

Pages